TRALI is thought to be triggered by recipient-specific anti-HLA class I or antibodies against neutrophils in donor plasma. Recently, anti-HLA class II have also been implicated. The prevalence of anti-HLA class II was investigated in normal volunteer platelet donors and in two nonfatal TRALI cases utilizing a flow-based assay. Potential target antigens also were investigated.
Joint Program in Transfusion Medicine, Harvard Medical School, and the Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
